Mecillinam의 임상분리 장내세균 대한 시험관내 항균력
In vitro Activities of Mecillinam Against Clinical Isolates of Enterobacteriaceae
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background:Mecillinam, an amidinopenicillin antibiotic, has been used to treat urinary tract infections and bacterial enteritis in many countries. In this study, we evaluated in vitro activity of mecillinam against Enterobacteriaceae isolates from urine, and Salmonella and Shigella isolates from patients with bacterial gastroenteritis. Materials and Methods:A total of 308 clinical strains were collected and were comprised of Escherichia coli (n=109), Klebsiella pneumoniae (n=52), Enterobacter spp. (n=30), Serratia marcescens (n=30) and Proteus spp. (n=29) isolated from a university hospital in Korea in 2007, and of Salmonella spp. (n=28) and Shigella spp. (n=30) isolated from Korean diarrheal patients from 2001 to 2006. Antimicrobial susceptibility was tested by Clinical Laboratory Standard Institute (CLSI) agar dilution method. CLSI breakpoint of mecillinam for E. coli urinary tract isolates was applied to all other isolates. Results:In E. coli, rate of susceptibility to ampicillin was 30%, but 99-100% to amikacin and cefotaxime. Most (96%) of E. coli isolates, including extended-spectrum β-lactamase (ESBL) producers, were susceptible to mecillinam. All ESBL producers, except for one isolate, were inhibited by ≤4 µg/mL of mecillinam. MIC90 of mecillinam for K. pneumoniae and Enterobacter spp. was 8 µg/mL and 1 µg/mL, respectively, and the susceptibility rate was 92% and 97%, respectively. However, MIC90 of mecillinam for S. marcescens isolates was >128 µg/mL and most of them were resistant to mecillinam. All Salmonella isolates and 27 of 30 Shigella isolates were susceptible to mecillinam. Conclusion:Mecillinam was active in vitro against most Enterobacteriaceae, Salmonella, and Shigella isolates except for S. marcescens. Therefore, mecillinam can be a good alternative agent for treating urinary tract infection and bacterial gastroenteritis.
Abstract
Background:Mecillinam, an amidinopenicillin antibiotic, has been used to treat urinary tract infections and bacterial enteritis in many countries. In this study, we evaluated in vitro activity of mecillinam against Enterobacteriaceae isolates from urine, and Salmonella and Shigella isolates from patients with bacterial gastroenteritis. Materials and Methods:A total of 308 clinical strains were collected and were comprised of Escherichia coli (n=109), Klebsiella pneumoniae (n=52), Enterobacter spp. (n=30), Serratia marcescens (n=30) and Proteus spp. (n=29) isolated from a university hospital in Korea in 2007, and of Salmonella spp. (n=28) and Shigella spp. (n=30) isolated from Korean diarrheal patients from 2001 to 2006. Antimicrobial susceptibility was tested by Clinical Laboratory Standard Institute (CLSI) agar dilution method. CLSI breakpoint of mecillinam for E. coli urinary tract isolates was applied to all other isolates. Results:In E. coli, rate of susceptibility to ampicillin was 30%, but 99-100% to amikacin and cefotaxime. Most (96%) of E. coli isolates, including extended-spectrum β-lactamase (ESBL) producers, were susceptible to mecillinam. All ESBL producers, except for one isolate, were inhibited by ≤4 µg/mL of mecillinam. MIC90 of mecillinam for K. pneumoniae and Enterobacter spp. was 8 µg/mL and 1 µg/mL, respectively, and the susceptibility rate was 92% and 97%, respectively. However, MIC90 of mecillinam for S. marcescens isolates was >128 µg/mL and most of them were resistant to mecillinam. All Salmonella isolates and 27 of 30 Shigella isolates were susceptible to mecillinam. Conclusion:Mecillinam was active in vitro against most Enterobacteriaceae, Salmonella, and Shigella isolates except for S. marcescens. Therefore, mecillinam can be a good alternative agent for treating urinary tract infection and bacterial gastroenteritis.
참고문헌 (29)
- Farmer 3rd JJ, "Enterobacteriaceae: Introduction and identification in Manual of clinical microbiology" (2003), ASM press
- 고은미, "1994-2003년 한 대학병원 혈액배양에서 분리된 미생물의 분포 및세균의 항균제 감수성 양상", The Korean Journal of Laboratory Medicine, 27(4), pp.265~275 (2007), 대한진단검사의학회
- Shin HB, "Isolation trend of enteropathogenic bacteria in 1969-1998", Korean J Clin Microbiol, 4, pp.87~95 (2001)
- Je-Chul Lee, "Epidemiology of Shigellosis in Korea", Journal of Bacteriology and Virology, 36(2), pp.41~50 (2006), 대한미생물학회
- 이용제, "청원군 일개 면에서 산발적으로 신고한 세균성이질 집단 발병 역학조사", 예방의학회지, 38(2), pp.182~188 (2005), 대한예방의학회
- 이혁민, "2005∼2006년 국내 12개 병원에서 분리된 주요 세균의 항균제 내성률", 대한임상미생물학회지, 10(1), pp.59~69 (2007), 대한임상미생물학회
- 이혁민, "2004년도 국내 12개 병원에서 분리된 주요 세균의 항균제 내성율", Annals of Clinical Microbiology, 8(1), pp.66~73 (2005), 대한임상미생물학회
- Falagas ME, "Potential of old-generation antibiotics to address current need for new antibiotics", Expert Rev Anti Infect Ther, 6, pp.593~600 (2008)
- Lund F, "6-amidinopenicillanic acids-a new group of antibiotics", Nat New Biol, 236, pp.135~137 (1972)
- Zhanel GG, "Mecillinam activity compared to ampicillin, trimethoprim", sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli, 1998, pp.44, 391~396
- Graninger W, "Pivmecillinam-therapy of choice for lower urinary tract infection", Int J Antimicrob Agents 22 Suppl, 2, pp.73~78 (2003)
- Skov R, "Susceptibility testing of urinary isolates of Escherichia coli to mecillinam using NCCLS methodology", Int J Antimicrob Agents, 25, pp.198~204 (2005)
- Hossain MA, "Increasing frequency of mecillinam-resistant shigella isolates in urban Dhaka and rural Matlab, Bangladesh: A 6 year observation", J Antimicrob Chemother, 42, pp.99~102 (1998)
- CLSI, "Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement", M100-s17. Clinical and Laboratory Standards Institute, Wayne, PA (2007)
- Bryskier A, "Antimicrobial agents: Antibacterials and antifungals" (2005), ASM Press
- 강지혜, "Ambler Class A Extended-Spectrum β-Lactamase 생성 Escherichia coli와 Klebsiella pneumoniae의국내분리현황", Annals of Clinical Microbiology, 8(1), pp.17~25 (2005), 대한임상미생물학회
- Lee SG, "Spread of CTX-M-type extended- spectrum β-lactamases among bloodstream isolates of Escherichia coli and Klebsiella pneumoniae from a Korean hospital", Diagn Microbiol Infect Dis, 63, pp.76~80 (2009)
- 홍성진, "충주지역에서 집단 발생한 Extended-spectrum -lactamase생성 Shigella sonnei 감염의 임상적 특성", The Korean Journal of Laboratory Medicine, 26(3), pp.168~173 (2006), 대한진단검사의학회
- Lee K, "Diversity of TEM-52 extended-spectrum β-lactamase- producing non-typhoidal Salmonella isolates in Korea", J Antimicrob Chemother, 52, pp.493~496 (2003)
- Lee K, "Prevalence of plasmid-mediated AmpC β-lactamases in Escherichia coli and Klebsiella pneumoniae in Korea", Microb Drug Resist, 12, pp.44~49 (2006)
- Mazzulli T, "Susceptibility of community gram-negative urinary tract isolates to mecillinam and other oral agents", Can J Infect Dis, 12, pp.289~292 (2001)
- Kahlmeter G, "An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: The ECO.SENS project", J Antimicrob Chemother, 51, pp.69~76 (2003), 69-76
- Sougakoff W, "Comparative potency of mecillinam and other β-lactam antibiotics against Escherichia coli strains producing different β-lactamases", J Antimicrob Chemother 46 Suppl, 1, pp.9~14 (2000)
- Richmond MH, "In vitro studies with mecillinam on Escherichia coli and Pseudomonas aeruginosa", J Antimicrob Chemother 3 Suppl, pp.29~39 (1977)
- Nicolle LE, "Successful treatment of CTX-M ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam", Scand J Infect Dis, 39, pp.748~749 (2007)
- Brenwald NP, "Activity of mecillinam against AmpC β-lactamase-producing Escherichia coli", J Antimicrob Chemother, 58, pp.223~224 (2006)
- Thomas K, "Activity of mecillinam against ESBL producers in vitro", J Antimicrob Chemother, 57, pp.367~368 (2006)
- Costa CS, "High-level resistance to mecillinam produced by inactivation of soluble lytic transglycosylase in Salmonella enterica serovar Typhimurium", FEMS Microbiol Lett, 256, pp.311~317 (2006)
- Ferry SA, "Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: The LUTIW project", Scand J Prim Health Care, 25, pp.49~57 (2007)